Primary entity: BAM15Class: Mitochondrial protonophore uncoupler — not a peptideCluster: Specialty / metabolic adjacent
BAM15 is a synthetic small-molecule mitochondrial protonophore uncoupler studied in cell and mouse models of metabolism and obesity — not a peptide and not FDA-approved. Uncoupling increases nutrient oxidation by dissipating the mitochondrial proton gradient independent of ATP synthase. That research interest sits near a historically dangerous uncoupler class (e.g., DNP folklore) — this page teaches class literacy, not DIY fat-loss chemistry.
BAM15 is not a peptide. It is a mitochondrial uncoupler tool compound. Peptide-shop adjacency is marketing, not pharmacology identity.
Mitochondrial uncouplers as a class have a serious historical toxicity story (classic DNP misuse). BAM15 was developed partly to improve selectivity vs older tools in research settings — that does not mean consumer self-experimentation is safe or approved. No protocols.
Not FDA-approved. Human clinical development as an approved obesity drug is not established in the sources cited here.
Key takeaways
- Not a peptide — mitochondrial protonophore uncoupler.
- Not FDA-approved; evidence largely cell + mouse.
- Class adjacency to dangerous historical uncouplers → extra YMYL refusal for dosing.
- No buy links or “BAM15 cycle” charts.
Questions this page answers
Next questions we answer on this page (curiosity / AI-gap map):
- What is BAM15?
- Also known as
- Classification
- What it is NOT
- Mechanism (uncoupling)
- Evidence ladder
- What’s been studied
- Safety literacy
- Regulatory status
- Why no dosages
- Related compounds
- Who for / not for
Who is this profile for — and who is it not for?
For: readers who see BAM15 next to peptides and need accurate mitochondrial-uncoupler literacy.
Not for: anyone seeking fat-loss chemistry protocols — hard refusal.
What is BAM15?
BAM15 is a lipophilic weak-acid mitochondrial uncoupler shown in research to stimulate respiration with improved selectivity profiles versus some classical uncouplers in vitro, and to affect obesity/insulin-resistance phenotypes in mice in published work. It is a research tool / investigational chemistry story, not a consumer peptide.
| Chemistry | Mitochondrial protonophore uncoupler |
|---|---|
| Peptide? | No |
| U.S. approval | Not approved |
| Evidence | Cell + mouse publications |
| YMYL note | Uncoupler class — no protocols |
Also known as
- BAM15 — primary research name.
- Descriptive: mitochondrial uncoupler BAM15.
- Mis-tags: “BAM15 peptide” — category error.
Wrong on both counts: not a peptide, and “safer than DNP in papers” is not permission for DIY use.
How is BAM15 classified?
Investigational / research small-molecule uncoupler. Filed here for SERP adjacency and chemistry-class correction.
What is BAM15 not?
| BAM15 is not… | Why that matters |
|---|---|
| A peptide | Small molecule |
| An approved weight-loss drug | No approval |
| Consumer-safe “mito booster” | Uncoupler class risk literacy |
| Something we dose or source | Refusal |
How is BAM15 thought to work?
As a protonophore, BAM15 shuttles protons across the inner mitochondrial membrane, uncoupling fuel oxidation from ATP synthesis and increasing energy expenditure in research models. Papers also discuss reduced plasma-membrane depolarization versus some classical uncouplers — a research advantage, not a DIY safety certificate.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Cell | Respiration / uncoupling validation | Cell |
| Animal | Diet-induced obesity / insulin resistance mouse studies | Animal |
| Human | Not established as approved therapy | None |
| Approved label | None | None |
What has BAM15 been studied for?
Published themes include obesity, insulin resistance, liver fat, and organ-protection models in animals. Studied in mice ≠ human-approved medicine.
What safety topics come up?
Uncoupler class history includes severe toxicity from misused agents (classic DNP). BAM15 research aims at a better therapeutic window in controlled science — that does not authorize self-experimentation. Hyperthermia risk themes are class-relevant literacy. Not medical advice; no risk-minimization protocol.
What is BAM15's regulatory status?
- U.S.: Not FDA-approved.
- Development: This page does not invent clinical-phase numbers from marketing materials.
Why doesn't this page include a dosage chart?
Hard refusal: uncoupler class + unapproved + protocol-seeking harm potential.
Related lab literacy
Not applicable peptide reconstitution. What are peptides?.
Related compounds and comparisons
- 5-Amino-1MQ — NNMT inhibitor (also not a peptide).
- ATX-304 — AMPK-pathway investigational oral.
- Cardarine — PPARδ agonist folklore agent.
- Tesofensine — monoamine reuptake inhibitor (not a peptide).
Frequently asked questions
Is BAM15 a peptide?
No.
Is BAM15 FDA approved?
No.
Is BAM15 like DNP?
Both are mitochondrial uncoupler *class* stories; BAM15 is a distinct research compound. Class risk literacy still argues against DIY use. No protocols.
Has it reversed obesity in mice?
Published mouse studies report metabolic benefits in models — not a human approval.
Why no dosage chart?
YMYL hard refusal for uncouplers.
Not a peptide. Uncoupler class risk literacy. Disclaimer.
Sources
The sources below were checked against PubMed, DailyMed, or the official agency page on November 10, 2026 (America/Phoenix). Links go to the publisher, PubMed, or the agency record.
- Primary — animal Axelrod CL, King WT, Davuluri G, et al. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Mol Med. 2020. doi:10.15252/emmm.202012088. PMID: 32519812. Preclinical study.
- Anti-doping World Anti-Doping Agency. The World Anti-Doping Code International Standard Prohibited List 2026. Accessed November 10, 2026. Confirm the current list and GlobalDRO before relying on sport status. The 2026 list names BAM15 as an example AMPK activator among metabolic modulators (S4.4). This is not an FDA-approved drug.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Oct 6, 2026 · Regulatory and sport-status wording checked November 10, 2026 against current FDA labels and the 2026 WADA Prohibited List · How we source & update
Educational disclaimer: Educational only. BAM15 is not a peptide. No dosing or buy links. We don’t sell peptides. Read our full disclaimers.